在长期心力衰竭中进行治疗评估
Marjorie Flores Chang1, Rohan Samson2, Amitabh Pandey3
1Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL-48, New Orleans, LA 70112, United States.
The American journal of the medical sciences
|February 2, 2025
概括
随着症状恶化,心力衰竭的指导指导医疗治疗与减少的射出分数可能会失去有效性. 本综述审查了观察数据,并提出了一种务实的方法来评估这些疗法在先进阶段的退出.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 指南导向医学疗法 (GDMT) 包含心力衰竭与减少喷射率 (HFrEF) 的四个支柱.
- 关键试验确定了稳定HFrEF患者 (NYHAII-III类) 的GDMT疗效,其事件发生率较低.
- 在晚期HFrEF阶段,症状恶化和预期寿命下降时,GDMT的益处尚未得到研究.
研究的目的:
- 审查关于GDMT支柱在高级HFrEF中的治疗价值的观察数据.
- 探索神经激素调节和心脏后负荷减轻晚期心血管或脏疾病的逐渐消失的好处.
- 提出一个务实的方法来收集关于在高级HFrEF中GDMT连续撤销的证据.
主要方法:
- 对研究GDMT在高级HFrEF中的疗效的观察性研究的综述.
- 关于神经激素调节和心脏后负荷减轻晚期疾病的证据分析.
- 关于收集关于撤销GDMT的数据的务实框架的建议.
主要成果:
- 观察性研究表明,神经激素调节和心脏后负荷减轻在晚期心血管或脏疾病中的益处正在减少.
- 关于GDMT在患有高级HFrEF的患者中有效性的数据有限.
- 确定需要基于证据的策略来管理GDMT在先进的HFrEF中.
结论:
- 在先进的HFrEF中,GDMT支柱的治疗价值可能会下降.
- 需要进一步的研究,以指导在这个人群中顺序取消GDMT.
- 为优化高级HFrEF的护理,建议采用实用性的证据收集方法.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:26Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338